2022 Top News from Drug Topics

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.

Results of a study at the Veterans Health Administration found that feedback and education led to better medication outcomes for patients.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.

Wolters Kluwer Health conducted a survey of just over 1000 respondents to get US adults’ feelings about notable trends in the pharmacy industry.